Finnish clinical-stage biopharmaceutical company Aplagon has closed a €7 million funding round led by Fåhraeus Startup and Growth (FSG) and the European Innovation Council (EIC) Fund. The round was also backed by Finnish investors the Jenny and Antti Wihuri Foundation, Innovestor, and the Gösta Serlachius Fine Arts Foundation, ArcticStartup reports.
About Aplagon
-
Founded by Riitta Lassila and associates at the Wihuri Research Institute, Aplagon is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for thromboinflammatory diseases, addressing critical unmet medical needs in vascular medicine.
-
APAC, the company’s lead therapeutic, is a heparin proteoglycan mimetic with dual antiplatelet and anticoagulant properties. It uniquely targets vascular injury sites, delivering localized, long-term action while minimizing systemic exposure.
-
The clinical pipeline focuses on thromboinflammatory conditions, with key indications in: Arteriovenous fistula (AVF) maturation failure in hemodialysis patients, and Chronic limb-threatening ischemia (CLTI) to prevent amputations and major cardiovascular events.
Investment details
The new funding round led by Fåhraeus Startup and Growth (FSG) and the European Innovation Council (EIC) Fund. The round also was backed by Finnish investors such as the Jenny and Antti Wihuri Foundation, Innovestor, and the Gösta Serlachius Fine Arts Foundation.
-
Fåhraeus Startup and Growth Fund is an early-stage venture capital fund which invests in life science and tech companies with groundbreaking innovative solutions.
-
The European Innovation Council Fund is the venture investment arm of the European Innovation Council (EIC). With a budget of €3.5 billion, it supports start-ups through patient capital to minimize the risk for private investors.
The funding will support the continuation of ongoing clinical trials, including studies for Arteriovenous Fistula maturation failure and peripheral arterial occlusive disease, as well as the initiation of Phase 2A trials for chronic limb-threatening ischemia.